Registry-listed formulations

Dazodalibep · chembl:CHEMBL4594331

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

4 source entries across 4 studies. This list may not include all unresolved or historical entries.

  • VIB4920Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • VIB4920Registry intervention

    Linked study entry; product equivalence not established

    View study and source
  • DazodalibepRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • DazodalibepRegistry product

    Named ingredient; product remains distinct

    Formulation reported by source: SOLUTION FOR INFUSION

    Named ingredient; exact form unconfirmed. This mention does not add to the molecule trial count.

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
2(40%)
Results Posted
67%(2 trials)

Phase Distribution

Phase 3
3
60%
Phase 2
2
40%

Phase Distribution

0

Early Stage

2

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
3(60.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(3)

Detailed Status

Completed3
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (40.0%)
Phase 33 (60.0%)

Trials by Status

active_not_recruiting120%
completed360%
recruiting120%

Recent Activity

2 active trials
Showing 5 of 5
completedphase_3

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

NCT06104124
recruitingphase_3

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

NCT06747949
active_not_recruitingphase_3

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408
completedphase_2

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

NCT04129164
completedphase_2

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

NCT04163991

Clinical Trials (5)

Showing 5 of 5 trials
NCT06104124Phase 3

A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

Completed
NCT06747949Phase 3

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

Recruiting
NCT06245408Phase 3

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

Active Not Recruiting
NCT04129164Phase 2

A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome

Completed
NCT04163991Phase 2

A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis

Completed

All 5 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Protein
Total Trials
5

External References

ChEMBL
CHEMBL4594331

Names & Codes

Research Codes

MEDI-4920VIB-4920